The difficulty in categorizing PPARγ activation in cancer therapy as beneficial or disadvantageous is also well-illustrated in a study from Baron and colleagues, who investigated the effects of ciglitazone in two different colon cancer cell lines: HT29 and SW480 cells. The gene discussed is PPARG; the disease is malignant colon neoplasm.